New lipid therapies: PCSK9 inhibitors
Pharmacologic therapy reduces cardiovascular risk in a variety of primary and secondary prevention clinical situations in addition to lifestyle modifications. Low density lipoprotein cholesterol (LDL-C) is a key mediator of atherogenesis. Most cholesterol guidelines propose specific LDL-C while rece...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-12-01
|
| Series: | Journal of Clinical and Translational Endocrinology Case Reports |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2214624516300132 |